AVRA
  • Home
  • About
    • Who we are
    • What we do
    • The rationale for AVRA
    • A robust vaccine pipeline
    • The global and national context
    • Expected benefits
    • Governance and management
  • Key Activities
    • Antigen surveillance
    • Vaccine platform technologies
    • Adjuvant development
    • Antigen discovery
    • Animal models
    • Vaccine immunity
    • Vaccine manufacturing partners
    • Clinical trials
    • Education and training
  • People
  • Partners
  • News and Events
  • Contact
Menu

News and events

First antigen test pilot in low prevalence COVID-19 settings signals challenges for rollout

First antigen test pilot in low prevalence COVID-19 settings signals challenges for rollout

Mar 2, 2021

read more
SARS-CoV-2 antibody signature

SARS-CoV-2 antibody signature

Mar 1, 2021

read more
Mapping an effective immune response to COVID-19

Mapping an effective immune response to COVID-19

Feb 11, 2021

read more
COVID variants and what they mean for the pandemic

COVID variants and what they mean for the pandemic

Feb 10, 2021

read more
New method to assist fast-tracking of vaccines for pre-clinical tests

New method to assist fast-tracking of vaccines for pre-clinical tests

Jan 19, 2021

read more
New defence against dengue and emerging mosquito-borne viruses

New defence against dengue and emerging mosquito-borne viruses

Jan 8, 2021

read more
Doherty Institute receives MRFF funding for COVID-19 vaccine Phase I clinical trial

Doherty Institute receives MRFF funding for COVID-19 vaccine Phase I clinical trial

Jan 3, 2021

read more
Improving vaccination rates by dispelling mistrust and conspiracy

Improving vaccination rates by dispelling mistrust and conspiracy

Dec 17, 2020

read more
Sydney to undertake clinical studies of needle-free vaccine patch

Sydney to undertake clinical studies of needle-free vaccine patch

Nov 23, 2020

read more
University of Sydney to advance COVID-19 DNA vaccine to human trials

University of Sydney to advance COVID-19 DNA vaccine to human trials

Sep 24, 2020

read more
CSL signs agreement with Australian Government for UQ vaccine supply

CSL signs agreement with Australian Government for UQ vaccine supply

Sep 20, 2020

read more
« Older Entries

Recent news

  • First antigen test pilot in low prevalence COVID-19 settings signals challenges for rollout
  • SARS-CoV-2 antibody signature
  • Mapping an effective immune response to COVID-19
  • COVID variants and what they mean for the pandemic
  • New method to assist fast-tracking of vaccines for pre-clinical tests

The people behind AVRA

A team of professionals across a wide range of disciplines has been assembled to launch AVRA, across 3 of Australia’s leading research Universities.

read more

ENQUIRIES

P 07 3346 1623  |  M 0499 880 791

The University of Queensland Logo The University of Sydney Logo The University of Melbourne Logo

© 2020 Australian Vaccine Response Alliance (AVRA)